Yuan Y Cheng

US Patent:

20130172343, Jul 4, 2013

Filed:

Aug 4, 2011

Appl. No.:

13/814232

Inventors:

Ana Elena Minatti - Santa Monica CA, US
Yuan Cheng - Newbury Park CA, US
Wenge Zhong - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 491/20
C07D 498/20
C07D 498/22
C07D 491/22

US Classification:

5142345, 546 15, 514278, 544 70, 5142328, 544 71, 544230, 514256, 546 18

Abstract:

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I: (I). In another embodiment, the compounds have a general Formula II: (II). In another embodiment, the compounds have a general Formula III: (III). Variables A, A, A, A, A, A, R, R, V, W, X, Y and Z of Formulas I, II and III are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formulas I, II and III, intermediates and processes useful for the preparation of compounds of Formulas I, II and III.

US Patent:

20200324775, Oct 15, 2020

Filed:

Apr 13, 2019

Appl. No.:

16/383601

Inventors:

Henry Schellhorn - Los Angeles CA, US
Yuan Cheng - Los Angeles CA, US

International Classification:

B60W 30/18
G08G 1/16
G05D 1/00
G08G 1/01

Abstract:

A method for autonomous vehicles to change lanes on a motorway may include steps of providing a computer system enabling an incoming vehicle that conducts lane change to negotiate with an incumbent vehicle that stays in its lane; generating first synchronous data on traffic density and traffic speed to the vehicles in both the transversal and longitudinal directions on the motorway; generating second synchronous data on traffic density and traffic speed to said vehicles for vehicles entering on the motorway and exiting the motorway; providing a summary of historical statistics on the first and second synchronous data to the vehicles; calculating a fair price of each lane of the motorway at a predetermined location, at a predetermined time and within a predetermined tolerance; and generating a protocol to change lanes, wherein said incoming vehicle pays said incumbent vehicle the fair price to move in front of the incumbent vehicle.

US Patent:

20140249104, Sep 4, 2014

Filed:

Feb 27, 2014

Appl. No.:

14/192710

Inventors:

- Thousand Oaks CA, US
Jonathan D. LOW - Tarzana CA, US
Jennifer R. ALLEN - Newbury Park CA, US
Jian CHEN - Camarillo CA, US
Ning CHEN - Thousand Oaks CA, US
Yuan CHENG - Newbury Park CA, US
Ted JUDD - Granada Hills CA, US
Qingyian LIU - Camarillo CA, US
Patricia LOPEZ - Woodland Hills CA, US
Wenyuan QIAN - Newbury Park CA, US
Shannon RUMFELT - Camarillo CA, US
Robert M. RZASA - Ventura CA, US
Nuria A. TAMAYO - Newbury Park CA, US
Qiufen XUE - Newbury Park CA, US
Bryant YANG - Agoura Hills CA, US
Wenge ZHONG - Thousand Oaks CA, US

International Classification:

C07D 413/14
C07F 7/08
C07D 513/04
C07D 413/12
C07D 471/04

US Classification:

514 63, 544 96, 5142288, 544 69

Abstract:

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A, A, A, A, each of Rand R, Rand Rof Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.